-+ 0.00%
-+ 0.00%
-+ 0.00%

Waldencast's Obagi Medical Announces DermFx As Key Partner For Aesthetics Leadership With Obagi's Hyaluronic Acid Program

Benzinga·02/06/2026 13:26:12
Listen to the news

Obagi Medical, a leading innovator in physician-dispensed skincare and aesthetic solutions and part of Waldencast plc (NASDAQ:WALD) ("Waldencast" or the "Company"), today announced DermFx as a key partner for the Aesthetics Leadership with Obagi's Hyaluronic Acid (ALOHA) Program. DermFx will help generate real-world data to translate the clinical safety and efficacy demonstrated in FDA pivotal trials into everyday practice across multiple locations and structured evaluation programs that will highlight the value of ALOHA to DermFx.